What’s New in PAH in 2024
Dr. Melissa Wilson discusses new treatments in the field of pulmonary hypertension in 2024, focusing on Sotatercept and combination therapy with Opsynvi. Dr. Wilson emphasizes the importance of patient selection and individualized treatment plans. She also discusses the initiation and monitoring of these therapies, as well as potential side effects and patient adherence.
Claim your 0.5 CME credits for listening to this episode here: https://forms.gle/42yHmF8UpemVhdDJA.
The Innovation of the Advanced Practice Respiratory Therapist (APRT)
As the physician shortage across the US continues to grow, the demand for medical care remains a void that needs to be […]
ILD: Bringing Resources & Bridging Specialties
In honor of Pulmonary Fibrosis Awareness Month, the APAPP ILD subcommittee has highlighted high-yield, quality information on Interstitial Lung Disease (ILD) that […]
Is this SOB my problem or yours? : Referral to Cardiology
Pediatric RSV Postpandemic Findings from Pulmonology Advisor
Pulmonology Advisor recently published an article titled “Pediatric RSV Postpandemic: Many More Hospital, ICU Admissions and ED Visits.” This report highlights a […]
Link Between Medication Adherence and PAP Therapy
Many patients with sleep apnea may also be on medication for other conditions. Understanding how a patient’s existing medication adherence habits can […]
Imposter Syndrome: Who me?
PeerDirect Program: The Role of APPs in ILD
In a recent PeerDirect program from Boehringer Ingelheim, Corinne Young, MSN, FNP-C, FCCP, and Jessica Glennie, CNP discuss the role of Advanced […]